Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Article Details
- CitationCopy to clipboard
Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF
Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Neuromolecular Med. 2004;6(2-3):87-92.
- PubMed ID
- 15970626 [ View in PubMed]
- Abstract
Administration of triacetyluridine (TAU) is a means of delivering exogenous pyrimidines to the brain, which may help to compensate for bioenergetic defects. TAU has previously been shown to be neuroprotective in animal models of Huntington's and Alzheimer's diseases. We examined whether oral administration of TAU in the diet could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity model of Parkinson's disease. Administration of TAU significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine-hydroxylase-positive neurons in the substantia nigra. These findings suggest that administration of TAU may be a novel approach for treating neurodegenerative diseases associated with impaired mitochondrial function.
DrugBank Data that Cites this Article
- Drugs